Supplement - Page 89

Abbott Laboratories (ABT) is drawing fresh scrutiny after sales declines in its Nutrition business, new product launches and pricing moves, and early signs of recovering volumes, all while analysts grow more cautious

In Q1 2026, Abbott Laboratories reported a modest earnings beat, closed its US$21.00 billion Exact Sciences acquisition to expand in cancer diagnostics, and outlined a new volume-led Nutrition strategy after a 6%

Cleveland Clinic Donates $1.25M to Children’s Hunger Alliance to Expand Preschool Nutrition Programs